Urinary Myeloid IgA Fc Alpha Receptor (CD89) and Transglutaminase-2 As New Biomarkers for Active IgA Nephropathy and Henoch-Schönlein Purpura Nephritis

Overview

Journal BBA Clin

Publisher Elsevier

Specialty Biochemistry

Date 2016 Apr 7

PMID 27051593

Citations 13

Authors

Rafael N Moresco

Marijn M Speeckaert

Slawomir C Zmonarski

Magdalena Krajewska

Ewa Komuda-Leszek

Agnieszka Perkowska-Ptasinska

Loreto Gesualdo

Maria T Rocchetti

Sigurd E Delanghe

Raymond Vanholder

Wim Van Biesen

Joris R Delanghe

Affiliations

Soon will be listed here.

Abstract

Background: IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) are glomerular diseases that share a common and central pathogenic mechanism. The formation of immune complexes containing IgA1, myeloid IgA Fc alpha receptor (FcαRI/CD89) and transglutaminase-2 (TG2) is observed in both conditions. Therefore, urinary CD89 and TG2 could be potential biomarkers to identify active IgAN/HSPN.

Methods: In this multicenter study, 160 patients with IgAN or HSPN were enrolled. Urinary concentrations of CD89 and TG2, as well as some other biochemical parameters, were measured.

Results: Urinary CD89 and TG2 were lower in patients with active IgAN/HSPN compared to IgAN/HSPN patients in complete remission (P < 0.001). The CD89xTG2 formula had a high ability to discriminate active from inactive IgAN/HSPN in both situations: CD89xTG2/proteinuria ratio (AUC: 0.84, P < 0.001, sensitivity: 76%, specificity: 74%) and CD89xTG2/urinary creatinine ratio (AUC: 0.82, P < 0.001, sensitivity: 75%, specificity: 74%). Significant correlations between urinary CD89 and TG2 (r = 0.711, P < 0.001), proteinuria and urinary CD89 (r = - 0.585, P < 0.001), and proteinuria and urinary TG2 (r = - 0.620, P < 0.001) were observed.

Conclusions: Determination of CD89 and TG2 in urine samples can be useful to identify patients with active IgAN/HSPN.

Citing Articles

IgA nephropathy.

Stamellou E, Seikrit C, Tang S, Boor P, Tesar V, Floege J Nat Rev Dis Primers. 2023; 9(1):67.

PMID: 38036542 DOI: 10.1038/s41572-023-00476-9.

Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies.

Zanoni F, Abinti M, Belingheri M, Castellano G Int J Mol Sci. 2023; 24(17).

PMID: 37685941 PMC: 10487514. DOI: 10.3390/ijms241713134.

IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.

Du Y, Cheng T, Liu C, Zhu T, Guo C, Li S Diagnostics (Basel). 2023; 13(2).

PMID: 36673113 PMC: 9857562. DOI: 10.3390/diagnostics13020303.

An Emerging Role for Neutrophil Extracellular Traps in IgA Vasculitis: A Mini-Review.

Chen X, Tu L, Tang Q, Huang L, Qin Y Front Immunol. 2022; 13:912929.

PMID: 35799774 PMC: 9253285. DOI: 10.3389/fimmu.2022.912929.

The Involvement of Neutrophil Extracellular Traps in Disease Activity Associated With IgA Vasculitis.

Chen X, Tu L, Zou J, Zhu S, Zhao Y, Qin Y Front Immunol. 2021; 12:668974.

PMID: 34539623 PMC: 8446352. DOI: 10.3389/fimmu.2021.668974.

References

Chou C, Streets A, Watson P, Huang L, Verderio E, Johnson T . A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain. J Biol Chem. 2011; 286(31):27825-35. PMC: 3149372. DOI: 10.1074/jbc.M111.226340. View

Floege J, Moura I, Daha M . New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol. 2014; 36(4):431-42. DOI: 10.1007/s00281-013-0411-7. View

Launay P, Grossetete B, Gaudin E, Torres S, Beaudoin L, Patey-Mariaud de Serre N . Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med. 2000; 191(11):1999-2009. PMC: 2213528. DOI: 10.1084/jem.191.11.1999. View

Julian B, Wittke S, Haubitz M, Zurbig P, Schiffer E, McGuire B . Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol. 2007; 25(5):467-76. DOI: 10.1007/s00345-007-0192-5. View

van der Boog P, van Zandbergen G, De Fijter J, Klar-Mohamad N, van Seggelen A, Brandtzaeg P . Fc alpha RI/CD89 circulates in human serum covalently linked to IgA in a polymeric state. J Immunol. 2002; 168(3):1252-8. DOI: 10.4049/jimmunol.168.3.1252. View

Grossetete B, Launay P, Lehuen A, Jungers P, Bach J, Monteiro R . Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. 1998; 53(5):1321-35. DOI: 10.1046/j.1523-1755.1998.00885.x. View

Floege J . The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?. Am J Kidney Dis. 2011; 58(6):992-1004. DOI: 10.1053/j.ajkd.2011.05.033. View

Berthelot L, Papista C, Maciel T, Biarnes-Pelicot M, Tissandie E, Wang P . Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med. 2012; 209(4):793-806. PMC: 3328362. DOI: 10.1084/jem.20112005. View

Moura I, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J . Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol. 2004; 15(3):622-34. DOI: 10.1097/01.asn.0000115401.07980.0c. View

10.

Narita I, Gejyo F . Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy. Clin Exp Nephrol. 2008; 12(5):332-338. DOI: 10.1007/s10157-008-0054-5. View

11.

Rocchetti M, Centra M, Papale M, Bortone G, Palermo C, Centonze D . Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics. 2007; 8(1):206-16. DOI: 10.1002/pmic.200700492. View

12.

Ben Mkaddem S, Rossato E, Heming N, Monteiro R . Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun Rev. 2012; 12(6):666-9. DOI: 10.1016/j.autrev.2012.10.011. View

13.

Appel G, Waldman M . The IgA nephropathy treatment dilemma. Kidney Int. 2006; 69(11):1939-44. DOI: 10.1038/sj.ki.5000434. View

14.

Leung J, Tsang A, Chan D, Lai K . Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol. 2000; 11(2):241-249. DOI: 10.1681/ASN.V112241. View

15.

Kiryluk K, Moldoveanu Z, Sanders J, Eison T, Suzuki H, Julian B . Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int. 2011; 80(1):79-87. PMC: 3641561. DOI: 10.1038/ki.2011.16. View

16.

Tissandie E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F . Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int. 2011; 80(12):1352-63. DOI: 10.1038/ki.2011.276. View

17.

Mohey H, Laurent B, Mariat C, Berthoux F . Validation of the absolute renal risk of dialysis/death in adults with IgA nephropathy secondary to Henoch-Schönlein purpura: a monocentric cohort study. BMC Nephrol. 2013; 14:169. PMC: 3733957. DOI: 10.1186/1471-2369-14-169. View

18.

Mestecky J, Tomana M, Moldoveanu Z, Julian B, Suzuki H, Matousovic K . Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res. 2008; 31(1):29-37. PMC: 2821435. DOI: 10.1159/000112922. View

19.

Counahan R, Winterborn M, White R, Heaton J, Meadow S, Bluett N . Prognosis of Henoch-Schönlein nephritis in children. Br Med J. 1977; 2(6078):11-4. PMC: 1631306. DOI: 10.1136/bmj.2.6078.11. View

20.

WALDO F . Is Henoch-Schönlein purpura the systemic form of IgA nephropathy?. Am J Kidney Dis. 1988; 12(5):373-7. DOI: 10.1016/s0272-6386(88)80028-3. View